QIAGEN N.V. has entered into an agreement to purchase all
outstanding shares of Shenzhen PG Biotech Co Ltd based in
Shenzhen, China. PG Biotech is a leading developer, manufacturer and supplier
of polymerase chain reaction (PCR)-based molecular diagnostic kits in China.
The acquisition will expand QIAGEN's position as a leading provider of
molecular Diagnostics solutions to OEM partners and customers in the rapidly
growing Asian markets. Read more about the terms of the acquisition here.